Why does tumor-free survival matter in the DMBA-TPA model for target validation?

Tumor-free survival reflects the initiation phase, allowing researchers to assess how genetic or pharmacological interventions affect the earliest steps of carcinogenesis. A statistically significant delay in papilloma onset indicates effective target modulation during initiation. This endpoint supports go/no-go decisions in early discovery by isolating initiation from promotion effects.

How does isolating DMBA as an initiator fit into the discovery pipeline?

DMBA acts as a mutagen that induces DNA damage and initiates tumor formation, enabling study of initiation as a discrete biological process. By separating initiation from TPA-driven promotion, researchers can evaluate compounds or genotypes that specifically affect mutagenic response or DNA repair. This isolation supports target validation in genotoxic stress pathways early in the pipeline.

What quantitative papilloma measurements enable lead identification in this model?

Papilloma count and size over time provide quantifiable metrics for tumor burden and progression rate, essential for dose-response analysis. These measurements allow comparison of experimental groups to identify leads that reduce multiplicity or growth. Consistent weekly tracking ensures reliable statistical power for hit-to-lead decisions.

Why are replication requirements critical for cross-functional collaboration in this model?

Replication ensures that observed differences in tumor initiation or progression are robust and not due to technical variability in chemical application or animal handling. Standardized protocols for DMBA/TPA dosing, timing, and measurement enable consistent results across sites and teams. This reproducibility supports reliable data sharing between discovery, preclinical, and translational groups.

What statistical analysis capabilities are required before implementing the DMBA-TPA model in a discovery setting?

The model requires survival analysis for tumor-free latency and count data modeling (e.g., Poisson or negative regression) for papilloma multiplicity. These analyses detect significant differences between control and experimental groups in initiation and progression. Access to biostatistical support ensures proper endpoint selection and interpretation for decision-making.

نموذج سرطان الجلد المستحث بالمواد الكيميائية باستخدام ثنائي ميثيل بنز [a] انثراسين و 12-O-Tetradecanoyl Phorbol-13-خلات (دمبا-طن سنويا)

14.9K مشاهدات

تم الاستشهاد 18 مرة

04:12 د

ديسمبر 19, 2019

10.3791/60445-v

ديسمبر 19, 2019

14.9K مشاهدات

Maria Vähätupa^*¹ , Toini Pemmari^*¹ , Ilkka Junttila¹^,² , Marko Pesu¹^,² , Tero A.H. Järvinen¹

¹Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, ²Department of Clinical Microbiology, Fimlab Laboratories

^* These authors contributed equally

ويسبب سرطان الجلد مرحلتين من قبل اثنين من المواد الكيميائية التطبيقية موضعيا. الطفرات 7 ، 12-ديميثيلبنز [a] انثراسين) يسبب طفرات في خلايا البشرة والتطبيق المستمر لمشجع النمو العام 12-O-tetradecanoyl phorbol-13-خلات يسرع تكوين الورم الحليمي الجلد.